Annual Report

The report describes Pharming's 2014 transition from FDA approval of Ruconest to its US launch through Salix, including a US$20.0 million milestone payment. Consolidated revenues reached €21.2 million, while the workforce grew to 57 people at year-end. Its CSR section highlights patient safety, animal welfare, responsible operations and environmental sustainability.